Zeitschrift für Zelluläre und Molekulare Pharmakologie

Offener Zugang

Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.

Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser

Abstrakt

Pharmacogenomics: Paving the Way for Personalized Medicine

Richard Feynman*

Pharmacogenomics, a field at the intersection of pharmacology and genomics, aims to uncover how an individual’s genetic makeup influences their response to drugs. By studying genetic variations that affect drug metabolism and efficacy, pharmacogenomics holds great promise for optimizing drug selection and dosage, thereby improving treatment outcomes and minimizing adverse effects. This article provides an overview of pharmacogenomics, its applications in personalized medicine, and the challenges associated with its implementation. Pharmacogenomics focuses on analyzing how an individual’s genetic variations affect drug response, metabolism, and toxicity. Genetic variations, known as single nucleotide polymorphisms (SNPs), can occur in genes encoding drug-metabolizing enzymes, drug targets, or transporters. These SNPs can lead to interindividual differences in drug efficacy and safety. The field of pharmacogenomics employs advanced technologies such as genome-wide association studies (GWAS) and next-generation sequencing (NGS) to identify genetic variants associated with drug response. Through these studies, researchers aim to establish predictive biomarkers that can guide clinicians in tailoring drug therapies based on an individual’s genetic profile.